St. Jude’s FAME II FFR Study Successful, But Impact Is Debated

Final results from the firm’s FAME II trial show the benefits of fractional flow reserve technology as an aid to patient selection for cardiac stenting, but because no heart attack or mortality reduction was found, the significance of the data is disputed.